(+)-JQ1

Name: (+)-JQ1
Brand: Selleck Chemicals
SKU: S7110
Rating: 5 (261 reviews)

For research use only.

Catalog No.S7110

261 publications

CAS No. 1268524-70-4

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy. (+)-JQ1 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes.

Selleck's (+)-JQ1 has been cited by 261 publications

Cell, 2020, 182(4):992-1008.e21

PubMed: 32710817 ( click the link to review the publication )

Nat Genet, 2020, 52(4):408-417

PubMed: 32203462 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):512-526

PubMed: 29533787 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Nat Med, 2017, 23(9):1046-1054

PubMed: 28805821 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009091

PubMed: 33411730 ( click the link to review the publication )

Mol Cancer Ther, 2021, molcanther.0809.2020

PubMed: 33509905 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 16;7(7):1902926

PubMed: 32274304 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202021450

PubMed: 33310900 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2246.2020

PubMed: 33109736 ( click the link to review the publication )

Cancer Res, 2020, canres.1030.2020

PubMed: 32934021 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):80

PubMed: 32552902 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):261

PubMed: 33239043 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2668

PubMed: 32962010 ( click the link to review the publication )

Cell Death Dis, 2020, 17;11(4):239

PubMed: 32303673 ( click the link to review the publication )

Br J Cancer, 2020, 4

PubMed: 32362655 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2020, 6;19:109-123

PubMed: 31837602 ( click the link to review the publication )

J Mol Cell Biol, 2020, 11;12(5):359-371

PubMed: 31565729 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(5):4547-4557

PubMed: 32163373 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(1):397-415

PubMed: 31901895 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(10):9240-9259

PubMed: 32392533 ( click the link to review the publication )

Carcinogenesis, 2020, 41(9):1282-1293

PubMed: 31826234 ( click the link to review the publication )

Epigenetics, 2020, 22:1-13

PubMed: 32164487 ( click the link to review the publication )

Cell Oncol (Dordr), 2020, 10.1007/s13402-020-00497-6

PubMed: 32166583 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3503-3515

PubMed: 32726482 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(1):148-163

PubMed: 32064158 ( click the link to review the publication )

Oncogenesis, 2020, 9(3):33

PubMed: 32157097 ( click the link to review the publication )

ACS Chem Biol, 2020, 17;15(4):895-903

PubMed: 32176478 ( click the link to review the publication )

J Immunol, 2020, 204(5):1242-1254

PubMed: 31988180 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:565820

PubMed: 33134168 ( click the link to review the publication )

J Cell Mol Med, 2020, 10.1111/jcmm.15901

PubMed: 32954665 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(2):1650-1657

PubMed: 31821686 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6873

PubMed: 32961679 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15837

PubMed: 32985581 ( click the link to review the publication )

Sci Rep, 2020, 10(1):19723

PubMed: 33184327 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00570-8

PubMed: 33311600 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00504-4

PubMed: 32855528 ( click the link to review the publication )

Int J Biol Macromol, 2020, 164:3204-3220

PubMed: 32860796 ( click the link to review the publication )
Front Pharmacol, 2020, 8;11:618

PubMed: 32457617 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Exp Cell Res, 2020, 24:112034

PubMed: 32339606 ( click the link to review the publication )

Med Sci Monit, 2020, 8;26:e923411

PubMed: 32266878 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0160

PubMed: 32703768 ( click the link to review the publication )

Cancer Cell, 2020, 37(4):584-598

PubMed: 32220301 ( click the link to review the publication )

Front Oncol, 2020, 9:1471

PubMed: 31993368 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01393-x

PubMed: 32747750 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002

PubMed: 32175692 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33222

PubMed: 32683685 ( click the link to review the publication )

Cancer Lett, 2020, 491:50-59

PubMed: 32735909 ( click the link to review the publication )

Inflamm Regen, 2020, 40:25

PubMed: 33072227 ( click the link to review the publication )

Blood Adv, 2020, 4(20):5062-5077

PubMed: 33080008 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):673

PubMed: 32826850 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Commun, 2019, 10(1):335

PubMed: 30659195 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3201

PubMed: 31324758 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Genome Res, 2019, 29(10):1659-1672

PubMed: 31515287 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2220-2225

PubMed: 30659143 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )
Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):277

PubMed: 31653272 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

Cancer Res, 2019, 79(19):4869-4881

PubMed: 31311807 ( click the link to review the publication )

Cancer Res, 2019, 79(18):4599-4611

PubMed: 31358529 ( click the link to review the publication )

Cell Rep, 2019, 28(13):3497-3509

PubMed: 31553917 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Oncogene, 2019, 38(47):7249-7265

PubMed: 31420604 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):383

PubMed: 31470872 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):557

PubMed: 31324754 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(11):815

PubMed: 31653826 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )
Sci Rep, 2019, 9(1):17369

PubMed: 31758083 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(14):4748-4758

PubMed: 31731295 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):1251

PubMed: 31881855 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )

J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

SLAS Discov, 2019, 24(2):142-157

PubMed: 30204533 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Can J Physiol Pharmacol, 2019, 97(11):1028-1034

PubMed: 31330113 ( click the link to review the publication )

Nucleic Acids Res, 2019, gkz1139

PubMed: 31822909 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0682-7

PubMed: 31862959 ( click the link to review the publication )

Phytomedicine, 2019, 67:153163

PubMed: 31901891 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354

PubMed: 30270106 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1532

PubMed: 29670088 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3815

PubMed: 30232459 ( click the link to review the publication )

EMBO J, 2018, 37(5)

PubMed: 29440228 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(40):E9317-E9324

PubMed: 30181285 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )
Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

J Med Chem, 2018, 61(2):453-461

PubMed: 28378579 ( click the link to review the publication )

Cancers (Basel), 2018, 10(1)

PubMed: 29346274 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29988031 ( click the link to review the publication )

Cells, 2018, 7(10)

PubMed: 30304769 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2796-2810

PubMed: 30242092 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(2)

PubMed: 29118124 ( click the link to review the publication )

Epigenetics Chromatin, 2018, 11(1):30

PubMed: 29884215 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Sci Rep, 2018, 8(1):998

PubMed: 29343723 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5808-5820

PubMed: 29475942 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2018, 59(1):132-143

PubMed: 29332125 ( click the link to review the publication )

Bioorg Med Chem, 2018, 26(1):25-36

PubMed: 29170024 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )
Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

Oncotarget, 2018, 9(41):26491-26506

PubMed: 29899872 ( click the link to review the publication )

Oncotarget, 2018, 9(71):33482-33499

PubMed: 30323893 ( click the link to review the publication )

Blood Adv, 2018, 2(23):3428-3442

PubMed: 30504235 ( click the link to review the publication )

Oncotarget, 2018, 9(11):9907-9924

PubMed: 29515779 ( click the link to review the publication )

Oncotarget, 2018, 9(83):35408-35421

PubMed: 30459933 ( click the link to review the publication )

JCI Insight, 2018, 3(19)

PubMed: 30282829 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(6):681-690

PubMed: 28437395 ( click the link to review the publication )

Nat Commun, 2017, 8:16078

PubMed: 28714472 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1067

PubMed: 29057925 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(36):E7554-E7563

PubMed: 28784769 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(27):E5352-E5361

PubMed: 28630312 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(43):E9135-E9144

PubMed: 29073110 ( click the link to review the publication )

Genes Dev, 2017, 31(12):1212-1227

PubMed: 28724615 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

J Am Soc Nephrol, 2017, 28(2):504-519

PubMed: 27436852 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )
Cell Rep, 2017, 21(10):2796-2812

PubMed: 29212027 ( click the link to review the publication )

Haematologica, 2017, 102(10):1776-1784

PubMed: 28751557 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Sci Signal, 2017, 10(508)

PubMed: 29208683 ( click the link to review the publication )

J Med Chem, 2017, 60(24):9990-10012

PubMed: 29172540 ( click the link to review the publication )

J Med Chem, 2017, 60(14):6289-6304

PubMed: 28650658 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1436-1449

PubMed: 28923910 ( click the link to review the publication )

Cancer Discov, 2017, 7(8):852-867

PubMed: 28408401 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1739-1750

PubMed: 28572168 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1054-1067

PubMed: 28336808 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(6):1155-1165

PubMed: 28246302 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):35-44

PubMed: 27707886 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(8):984-997

PubMed: 28442587 ( click the link to review the publication )

Sci Rep, 2017, 7(1):8027

PubMed: 28808321 ( click the link to review the publication )

Skelet Muscle, 2017, 7(1):16

PubMed: 28870238 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

J Agric Food Chem, 2017, 65(22):4384-4394

PubMed: 28471170 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Molecules, 2017, 23(1)

PubMed: 29295560 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2581-2593

PubMed: 28553123 ( click the link to review the publication )
J Gen Virol, 2017, 98(4):799-809

PubMed: 28113052 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29558-29573

PubMed: 28418907 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37140-37153

PubMed: 28415755 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8334-8349

PubMed: 29492199 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98068-98083

PubMed: 29228674 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

J Chem Inf Model, 2017, 57(7):1677-1690

PubMed: 28636361 ( click the link to review the publication )

Oncotarget, 2017, 8(12):19478-19490

PubMed: 28061448 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(7):504-10

PubMed: 27159579 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(42):11865-11870

PubMed: 27679845 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(31):E4558-66

PubMed: 27432991 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(17):4440-51

PubMed: 27103402 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1204-13

PubMed: 26837760 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1313-9

PubMed: 26759243 ( click the link to review the publication )

Cell Rep, 2016, 16(5):1366-1378

PubMed: 27425608 ( click the link to review the publication )
Cell Rep, 2016, 15(2):310-22

PubMed: 27050521 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Clin Epigenetics, 2016, 8:76

PubMed: 27437033 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Cancer Discov, 2016, 6(6):612-29

PubMed: 27099234 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1217-26

PubMed: 26983878 ( click the link to review the publication )

J Virol, 2016, 90(18):8059-73

PubMed: 27356901 ( click the link to review the publication )

J Biol Chem, 2016, 291(41):21694-21702

PubMed: 27576686 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )

Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(48):79637-79653

PubMed: 27793034 ( click the link to review the publication )

Blood, 2015, 126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

Nat Commun, 2015, 6:10091

PubMed: 26631872 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Cancer Res, 2015, 75(21):4548-59

PubMed: 26483207 ( click the link to review the publication )

J Hematol Oncol, 2015, 8:121

PubMed: 26515759 ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Arch Toxicol, 2015, 89(2):179-91

PubMed: 25559776 ( click the link to review the publication )
Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Sci Rep, 2015, 5:10120

PubMed: 25944566 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(11):8722-35

PubMed: 25749378 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Nat Chem Biol, 2014, 10(4):305-12

PubMed: 24584101 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):E2721-30

PubMed: 24979794 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2014, 111(26):9503-8

PubMed: 24979803 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(11):2898-909

PubMed: 24714777 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5999-6009

PubMed: 25164011 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(11):2896-910

PubMed: 25106422 ( click the link to review the publication )

Epigenetics, 2014, 9(4):611-20

PubMed: 24496381 ( click the link to review the publication )

Drug Metab Dispos, 2013, 41(10):1725-31

PubMed: 23918665 ( click the link to review the publication )

PLoS One, 2013, 8(5):e63563

PubMed: 23704919 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Handb Exp Pharmacol, 2011, 206:1-12

PubMed: 21879443 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	MkXnR4VtdCCYaXHibYxqfHliQYPzZZk>	MmPQNlUxNzVyMD:xNFAxKG6P	NVnlVHVWOjRxNEivO\|IhcA>?	NW\n[XNWTE2VTx?=	MknXbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=>	M1vHSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{C3PFgyLz5{NkewO\|g5OTxxYU6=
BCPAP	NYrJZYk2S2WubDDWbYFjcWyrdImgRZN{[Xl?	M{PNTlI2OC93MECvNVAxOCCwTR?=	NGHGXowzPC92OD:3NkBp	M4PzdWROW09?	NIrBUWZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	NYDJdVFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3NFc5QDFpPkK2O\|A4QDhzPD;hQi=>
K1	Mof1R4VtdCCFeXPs[UBCe3OjeR?=	NVjYW5psOjVyL{WwNE8yODByIH7N	Mof3O\|IhcA>?	NGLReodFVVOR	NXTOUY9y[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl	MnXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5MEe4PFEoRjJ4N{C3PFgyRC:jPh?=
BCPAP	MkDMR4VtdCCFeXPs[UBCe3OjeR?=	MoG4NlUxNzVyMD:xNFAxKG6P	M3zUWFczKGh?	MXzEUXNQ	NHPjWZVienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS\|EheGijc3W=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjdyN{i4NUc,OjZ5MEe4PFE9N2F-
Hep3B	M3;yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLoNE0yOCEQvF2=	NHzjUGg2KGR?	NFrE[4tFVVOR	NESyTmRKSzVyPUCuNFgh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
HCCLM3	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWn3TGx[OC1zMDFOwG0>	MUm1JIQ>	MnzqSG1UVw>?	NFHISpVKSzVyPUCuNVQh\|ryP	NYfl[ZVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
HuH7	NYTWO2ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LXOVAuOTBizszN	Mly4OUBl	MkjoSG1UVw>?	MoTiTWM2OD1yLkKxJO69VQ>?	MlPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3N{WxOlcoRjJ4NUe1NVY4RC:jPh?=
HepG2	NEjSO\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW\u[ollOC1zMDFOwG0>	MkjsOUBl	NIn3dYRFVVOR	NGfQZpVKSzVyPUCuN\|Qh\|ryP	NX\IO3l3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
SMMC7721	NHj0eWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYGwMVExKM7:TR?=	MY[1JIQ>	MlnYSG1UVw>?	MmfCTWM2OD1yLkSxJO69VQ>?	NEPMOoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
BEL7402	M1rRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUiwMVExKM7:TR?=	NF7ieWQ2KGR?	NIn2PIlFVVOR	Ml3kTWM2OD1yLkS3JO69VQ>?	M2nDVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
MHCC97H	NUWwR2dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NECxOXkxNTFyIN88US=>	Mo[xOUBl	NXz3cGVrTE2VTx?=	MWPJR\|UxRTBwNEGg{txO	NXTreIR5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1O\|UyPjdpPkK2OVc2OTZ5PD;hQi=>
Hep3B	MVjD[YxtKEO7Y3zlJGF{e2G7	MkPwNE4yNzBwNT:yMlUh\|ryP	NXGyOop2PDhiaB?=	NVH5TW55TE2VTx?=	MXTs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV5NUG2O{c,OjZ3N{WxOlc9N2F-
HCCLM3	MmjXR4VtdCCFeXPs[UBCe3OjeR?=	Mnu0NE4yNzBwNT:yMlUh\|ryP	MnzPOFghcA>?	NInvW\|dFVVOR	MXns[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA>	NHy2Zms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
Hep3B	MUTBdI9xfG:\|aYOgRZN{[Xl?	MX2wMlEwOC53L{KuOUDPxE1?	NEnyT4s1QCCq	MonFSG1UVw>?	NF70TJFi[3SrdnH0[ZMh[2G\|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW\|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj	NEDBS2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW3OVE3Pyd-Mk[1O\|UyPjd:L3G+
HCCLM3	M1\JeWFxd3C2b4Ppd{BCe3OjeR?=	M1O2WlAvOS9yLkWvNk42KM7:TR?=	MlrUOFghcA>?	MoHWSG1UVw>?	M3Psd4FkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO\|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF?	M3HFWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUe1NVY4Lz5{NkW3OVE3PzxxYU6=
A549	M4TWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPONE4yNTFyIN88US=>	MmfJO\|IhcA>?		NGTQVotqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2jhO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H157	NV;rPFNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLKS4kxNjFvMUCg{txO	Mn\pO\|IhcA>?		M2LKeolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M{LV[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H1299	MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWf3T4NXOC5zLUGwJO69VQ>?	NWfFeYdZPzJiaB?=		MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NHzlSlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxOVIzPSd-Mk[0NVUzOjV:L3G+
A549	NF7iSGVHfW6ldHnvckBCe3OjeR?=	M{ny[\|EwOi53L{Wg{txO	NV\0W2xjOTJiaB?=		M1vqUOKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN?	M1nPXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H1299	MYHGeY5kfGmxbjDBd5NigQ>?	MYexM\|IvPS93IN88US=>	M1\2NlEzKGh?		MoL2xsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>?	M{HvTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEG1NlI2Lz5{NkSxOVIzPTxxYU6=
H157	MYnGeY5kfGmxbjDBd5NigQ>?	M2e1SlEwOi53L{Wg{txO	NH7Yb2kyOiCq		MUnk[YNz\WG\|ZXSgSHI1KGW6cILld5Nqd25?	NETYZlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkSxOVIzPSd-Mk[0NVUzOjV:L3G+
H1299	NVfhUXNyTnWwY4Tpc44hSXO\|YYm=	MkPqNU8zNjVxNTFOwG0>	NFXtRZMyOiCq		MlzZ[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRzNUKyOUc,OjZ2MUWyNlU9N2F-
C8161	NEH1endE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NX63XI46OC1{IN88US=>	NIPMSng1KGR?	MnPISG1UVw>?	NVXDS3hr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M2\F[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
Mel285	MoCxR4VtdCCYaXHibYxqfHliQYPzZZk>	NU\TR4lrOC1{IN88US=>	MUS0JIQ>	NHy3[Y1FVVOR	M4TIdYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFrpfZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
Mel290	NVzlfZJyS2WubDDWbYFjcWyrdImgRZN{[Xl?	Mn;HNE0zKM7:TR?=	M{PYeVQh\A>?	MXrEUXNQ	Ml30[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{KyN{c,OjZ\|OUeyNlM9N2F-
92.1	MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MnnFNE0zKM7:TR?=	MnzsOEBl	M4jZc2ROW09?	NWHkdJBH\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	Mn3wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Omm1.3	NYDq[FJRS2WubDDWbYFjcWyrdImgRZN{[Xl?	MUiwMVIh\|ryP	NHfHRVI1KGR?	NIr3b3FFVVOR	MmPv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MofYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|OUeyNlMoRjJ4M{m3NlI{RC:jPh?=
Mel202	NGT5dHdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVzXNXpIOC1{IN88US=>	NYfJclB2PCCm	MYjEUXNQ	MYHk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NULLPG01RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Mel270	Mn3jR4VtdCCYaXHibYxqfHliQYPzZZk>	MX:wMVIh\|ryP	NE\URWs1KGR?	NFzWVpZFVVOR	MUTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M3zn[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{m3NlI{Lz5{NkO5O\|IzOzxxYU6=
Omm1	NH;xb4pE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MX2wMVIh\|ryP	MlzOOEBl	MlzpSG1UVw>?	NUHKPZZL\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NX7OV2dxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
92.1	MoLJRZBweHSxc3nzJGF{e2G7	MX21NFAhdk1?	M{DNU\|Q5KGh?	NE\GTlhFVVOR	MWTpcoR2[2W\|IHHwc5B1d3Orcx?=	NUi0dlZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zPVczOjNpPkK2N\|k4OjJ\|PD;hQi=>
Omm1.3	MnPBRZBweHSxc3nzJGF{e2G7	M1\iOFUxOCCwTR?=	MnvjOFghcA>?	M1vUcGROW09?	NGLpdGVqdmS3Y3XzJIFxd3C2b4Ppdy=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{KyN{c,OjZ\|OUeyNlM9N2F-
92.1	NXfvcJdUS2WubDDDfYNt\SCDc4PhfS=>	NX2xdHJ5PTByIH7N	MmH1NlQwPDhxN{KgbC=>	M{O0T2ROW09?	NH7RRWFqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN7N{KyN{c,OjZ\|OUeyNlM9N2F-
Omm1.3	M1TLcWNmdGxiQ4njcIUhSXO\|YYm=	NXr1WmhiPTByIH7N	MUiyOE81QC95MjDo	M2jpZWROW09?	MWXpcoR2[2W\|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC\|dXKtS\|HDqA>?	NFPWOG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO5O\|IzOyd-Mk[zPVczOjN:L3G+
A549	MlvTSpVv[3Srb36gRZN{[Xl?	MmrzNVAxNzRyMD:xNFAxKG6P	MY[yOEBp		NHfVT4p2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz	MkjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUKxPVkoRjJ4MkGyNVk6RC:jPh?=
MCF-7	MXPGeY5kfGmxbjDBd5NigQ>?	M1PGUVExOC92MECvNVAxOCCwTR?=	NEjHRmozPCCq		NH;SWmF2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz	M1PUVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkGyNVk6Lz5{NkKxNlE6QTxxYU6=
HEK293	MlfJSpVv[3Srb36gRZN{[Xl?	MmO3NVAxNzRyMD:xNFAxKG6P	NHL1UJMzPCCq		M3i5TZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF?	NE\KWoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKxNlE6QSd-Mk[yNVIyQTl:L3G+
858	M2i1bmNmdGxiVnnhZoltcXS7IFHzd4F6	MmPBNE0yKM7:TR?=	MYq1JIQ>	NVjLU3BWTE2VTx?=	M4O3VoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MoX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[zN\|MoRjJ4MkC2N\|M{RC:jPh?=
DDR2L63V	NFHG[XJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFG2[lMxNTFizszN	MXO1JIQ>	MlLsSG1UVw>?	M1fEe4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	Ml7FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{ME[zN\|MoRjJ4MkC2N\|M{RC:jPh?=
BE(2)-C	MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NUfFcY5GOSEQvF2=	M4HRclEuPCCm		Moru[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4N{S2OEc,OjZyNke0OlQ9N2F-
IMR-32	NUizO3RXS2WubDDWbYFjcWyrdImgRZN{[Xl?	NV70PJRnOSEQvF2=	NI[0fmYyNTRiZB?=		NXrk[ok3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNke0OlQoRjJ4ME[3OFY1RC:jPh?=
JF	MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MoHtNUDPxE1?	MkDHNU01KGR?		MnL4[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	M3nPXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4ME[3OFY1Lz5{NkC2O\|Q3PDxxYU6=
BE(2)-M17	Ml64R4VtdCCYaXHibYxqfHliQYPzZZk>	MX6xJO69VQ>?	NVzkXXd5OS12IHS=		NYTYTlc2\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	NUm1XplWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOlc1PjRpPkK2NFY4PDZ2PD;hQi=>
SK-N-SH	M1\tZWNmdGxiVnnhZoltcXS7IFHzd4F6	NHPHXmIyKM7:TR?=	M{L2ZlEuPCCm		Mlvq[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	M2X5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4ME[3OFY1Lz5{NkC2O\|Q3PDxxYU6=
SK-N-DZ	MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NYjyU25sOSEQvF2=	NFj1dWkyNTRiZB?=		MmTn[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	NGP2dFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC2O\|Q3PCd-Mk[wOlc1PjR:L3G+
HMC-1.1	NILsb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHP4TXQ2NTVyMECgcm0>	NYjSUXRXPDhiaB?=	M1;VT2ROW09?	NXHDe5E{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUWzNFMoRjJ4MEW1N\|A{RC:jPh?=
HMC-1.2	M4\VWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\aOU02ODByIH7N	M2PaVlQ5KGh?	M{DCSWROW09?	MmL3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3vZeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
ROSA KIT WT	NUi3NW05T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXyS3VwPS13MECwJI5O	MoPrOFghcA>?	MoXBSG1UVw>?	NI\M[XdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MoDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUWzNFMoRjJ4MEW1N\|A{RC:jPh?=
ROSA KIT D816V	NXzBfGdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnPOU02ODByIH7N	NIK3PYg1QCCq	MnXFSG1UVw>?	M2rYcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NGXQ[ZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVMxOyd-Mk[wOVU{ODN:L3G+
HMC-1.1	M1rQe2Fxd3C2b4Ppd{BCe3OjeR?=	NEHnOmczODBvNUCwNEBvVQ>?	M3fXdlQ5KGh?	NXX4ZoZtTE2VTx?=	M3PBSYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
HMC-1.2	M4XNT2Fxd3C2b4Ppd{BCe3OjeR?=	M3PoR\|IxOC13MECwJI5O	MVm0PEBp	MUnEUXNQ	MWLpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3fUOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1N\|A{Lz5{NkC1OVMxOzxxYU6=
ROSA KIT WT	NVX0UI1kSXCxcITvd4l{KEG\|c3H5	NHHOc4QzODBvNUCwNEBvVQ>?	NVjjOIFVPDhiaB?=	NF:5PZlFVVOR	NIToRolqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFXIbm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC1OVMxOyd-Mk[wOVU{ODN:L3G+
ROSA KIT D816V	MkHXRZBweHSxc3nzJGF{e2G7	NXvqVY9oOjByLUWwNFAhdk1?	MWG0PEBp	NGC2e\|NFVVOR	M2e1Wolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUOwN{c,OjZyNUWzNFM9N2F-
494H	NEHONI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYntVHFbPzJiaB?=	M37COWROW09?	NELV[3lKSzVyPUCuNVIzyrFyLkCwOEDPxE1?	NEfmbVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
493H	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1HESlczKGh?	NIGzT\|ZFVVOR	M1PNfWlEPTB;MD6wOFfDuTBwMEC5JO69VQ>?	Mk\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
716H	NIHRdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEjMe284OiCq	M3vrUGROW09?	NFi4NFFKSzVyPUCuNlEzyrFyLkCzOEDPxE1?	NVHm[Gs2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
148I	M3fwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3vJSFczKGh?	MV3EUXNQ	MVfJR\|UxRTBwMki0xtExNjB\|NTFOwG0>	M13xbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
98Sc	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\BO\|IhcA>?	NFTqUW5FVVOR	NFHkOpBKSzVyPUCuNVE2yrFyLkCwOEDPxE1?	M4n4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
89R	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUW3NkBp	M1HWbGROW09?	MWLJR\|UxRTBwMUK2xtExNjByMzFOwG0>	NUjkToQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
494L	NHO2fIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NW\hV\|JqPzJiaB?=	Ml7VSG1UVw>?	MnvTTWM2OD1yLkOxO:KyOC5yMUKg{txO	M3T1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
493L	NUW0eVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYTtR\|c4PzJiaB?=	M3XaU2ROW09?	MUDJR\|UxRTBwMEWwxtExNjBzMTFOwG0>	Mn7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148L	NFjyO4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFfNVGM4OiCq	MWPEUXNQ	MoHTTWM2OD1yLkG0OuKyOC5yMUeg{txO	NYPSfpVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
98L	NYPQbGhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2T2T\|czKGh?	M1u3bmROW09?	NU\OTG5mUUN3ME2wMlMxQcLzMD6wNlkh\|ryP	NWnkdYdTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
OS17	NV\rTVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYK3NkBp	M1jQ[mROW09?	NGPXOHBKSzVyPUCuNFc6yrFyLkCwN{DPxE1?	M4\2b\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS9	M{jXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3fITlczKGh?	MmKySG1UVw>?	NXHDc21NUUN3ME2wMlQxPsLzMD6wNlgh\|ryP	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
MG63	NUDVSmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3\uS\|czKGh?	NGG1SnNFVVOR	M1;NbmlEPTB;MD6xNVTDuTBwMEK1JO69VQ>?	M{LL[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
SAOS2	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWG3NkBp	NHm2OVBFVVOR	MYXJR\|UxRTBwMkG3xtExNjByMzFOwG0>	NVLhTWRMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
U2OS	NU\PPGlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1jIelczKGh?	Mn;1SG1UVw>?	MmTGTWM2OD1yLkG5POKyOC5yMEig{txO	M4\ETFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
SJSA-1	M1PkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlW4O\|IhcA>?	NYHWcIE3TE2VTx?=	M3nv[WlEPTB;MD6xNFDDuTBwMEGwJO69VQ>?	NHnZbXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0OFU3Pid-MkW5OFQ2PjZ:L3G+
494H	NGjZdHRCeG:ydH;zbZMhSXO\|YYm=	M3G2OFAvOjVxMD61M\|EvOCEQvF2=	Mmf3NlQhcA>?	MnfqSG1UVw>?	MULpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	Moe5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148I	NH\EOoZCeG:ydH;zbZMhSXO\|YYm=	MXuwMlI2NzBwNT:xMlAh\|ryP	M4DQZVI1KGh?	M370b2ROW09?	NVrTSGxicW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li	M2DGXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS0OVY3Lz5{NUm0OFU3PjxxYU6=
OS17	MVfBdI9xfG:\|aYOgRZN{[Xl?	NH3mZnYxNjJ3L{CuOU8yNjBizszN	NXu4TGtKOjRiaB?=	MmPESG1UVw>?	MYDpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	NVnRe4poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFQ2PjZpPkK1PVQ1PTZ4PD;hQi=>
494H	NGfFVYpCeG:ydH;zbZMhSXO\|YYm=	M4DkflHjiIoQvF2=	M13HdVQ5KGh?	NHXkNnZFVVOR	MoTlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	MluxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
148I	NIXHWpJCeG:ydH;zbZMhSXO\|YYm=	MVKx5qCK\|ryP	NG\WZW41QCCq	M320bmROW09?	M1m5Oolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=>	MnqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NES1OlYoRjJ3OUS0OVY3RC:jPh?=
OS17	NH;0cIlCeG:ydH;zbZMhSXO\|YYm=	MmLxNgKBkc7:TR?=	NF3ST\|M1QCCq	NH\pdG5FVVOR	Mmq4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NEW2Okc,OjV7NES1OlY9N2F-
MOLM13	NF72c4ZCeG:ydH;zbZMhSXO\|YYm=	NGDkcYYzPTBibl2=	NFzpeHk1QCCq	MXnEUXNQ	MmHnbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk	M322eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPFI2Lz5{NUC1N\|gzPTxxYU6=
MV4-11	NHPye\|ZCeG:ydH;zbZMhSXO\|YYm=	M3LzelI2OCCwTR?=	MXm0PEBp	NU\GcI5VTE2VTx?=	NUfyOmFmcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni	Mnv3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MOLM13	M3;rUGZ2dmO2aX;uJGF{e2G7	MlXLNlUxKG6P	M2rtXVI1KGh?	MULEUXNQ	MV\lcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3M{iyOUc,OjVyNUO4NlU9N2F-
MV4-11	MoPXSpVv[3Srb36gRZN{[Xl?	MWKyOVAhdk1?	NHT5WXIzPCCq	M1vTTmROW09?	MlPB[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3M{iyOUc,OjVyNUO4NlU9N2F-
MOLM13	MXLBdI9xfG:\|aYOgRZN{[Xl?	NYPqbnZrOjVyIH7N	MkGyOFghcA>?	Mn\BSG1UVw>?	MkHxbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>?	MkfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUO4NlUoRjJ3MEWzPFI2RC:jPh?=
MV4-11	MUHBdI9xfG:\|aYOgRZN{[Xl?	MkXGNlUxKG6P	M1K0SFQ5KGh?	MnrySG1UVw>?	NVTybYNicW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?=	M3zrZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEWzPFI2Lz5{NUC1N\|gzPTxxYU6=
Hela	MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3:xXVAuPTByIH7N	MkKzO\|IhcA>?	NH[wNI1FVVOR	MVTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NXn1fVNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
HBL-1	MoDHR4VtdCCYaXHibYxqfHliQYPzZZk>	NWXhOZZ2OC13MECgcm0>	NHfX[Hk4OiCq	NXPIN5pTTE2VTx?=	M4jGZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M17m[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
HLY-1	MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2W3dFAuPTByIH7N	NIHRN4c4OiCq	NXL4O4ZuTE2VTx?=	NEG2NJFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXjyNoluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
OCI-Ly3	NEL4WXlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NHyxXpAxNTVyMDDuUS=>	NEfRZms4OiCq	Mn;OSG1UVw>?	NFfqWVdl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFv1b4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly10	M1ewS2NmdGxiVnnhZoltcXS7IFHzd4F6	M1;mOVAuPTByIH7N	MojsO\|IhcA>?	MUDEUXNQ	NEe2b5Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFT1dWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
SU-DHL-4	M3i1[mNmdGxiVnnhZoltcXS7IFHzd4F6	Mn3MNE02ODBibl2=	MUm3NkBp	NWizbG97TE2VTx?=	NGn1OpZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-5	Mn7HR4VtdCCYaXHibYxqfHliQYPzZZk>	M{HUT\|AuPTByIH7N	NEG3b5U4OiCq	M2LLVGROW09?	NYD3UZZq\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1fnUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-6	NGTxXVFE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFrvVIMxNTVyMDDuUS=>	Mnn3O\|IhcA>?	NFixfmxFVVOR	MYfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	NXHCfIdRS2WubDDWbYFjcWyrdImgRZN{[Xl?	NEfubmgxNTVyMDDuUS=>	MVe3NkBp	MmjwSG1UVw>?	NVjVb2oz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MlHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMEmyPVUoRjJ3MEC5Nlk2RC:jPh?=
RC-K8	NFXH[YlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXHYbnhYOC13MECgcm0>	NWnObXpHPzJiaB?=	M4HBbGROW09?	NEL2dXFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M4f2elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
OCI-Ly8	MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NEG0[\|AxNTVyMDDuUS=>	MnzLO\|IhcA>?	NYj5R3M4TE2VTx?=	NHrGZm9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCL-Ly18	M1rTXmNmdGxiVnnhZoltcXS7IFHzd4F6	NIfsR4UxNTVyMDDuUS=>	MXO3NkBp	M1XEXGROW09?	MXfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NF\Pe449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly3	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGn5cYcyPzJxMkWwM\|UxOCCwTR?=	MWSyM\|ch\A>?	NXvZSY5DTE2VTx?=	Mn\lbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW\|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
OCI-Ly8	NIXqT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWG0ZXd5OTd{L{K1NE82ODBibl2=	MmO3Nk84KGR?	MWHEUXNQ	NHPoNJVqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg	M1q4NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
SU-DHL-4	NWrwdlE4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFq2[5cyPzJxMkWwM\|UxOCCwTR?=	MXyyM\|ch\A>?	Mnz5SG1UVw>?	Mni4bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW\|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?=	NInTXHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
SU-DHL-10	NXfEW4JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7WUmY2OTd{L{K1NE82ODBibl2=	M4XSc\|IwPyCm	M{DCVWROW09?	NXjTRpRJcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC\|dXKtS\|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=>	NHXBUnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
OCI-Ly3	MkDDRZBweHSxc3nzJGF{e2G7	NUjsWZBJOTd{L{K1NEBvVQ>?	M2jLRldl	Mo\oSG1UVw>?	NV65S5dycW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	M3;nV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEC5Nlk2Lz5{NUCwPVI6PTxxYU6=
OCI-Ly8	MljiRZBweHSxc3nzJGF{e2G7	NFfkS5cyPzJxMkWwJI5O	NVv3SYhjP2R?	M3SxUWROW09?	MoHybY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC\|aXfubYZq[2GwdHz5	NGfyOYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCwPVI6PSd-MkWwNFkzQTV:L3G+
SU-DHL-4	M{DrdGFxd3C2b4Ppd{BCe3OjeR?=	M3y4SVE4Oi9{NUCgcm0>	M33uW\|dl	MVjEUXNQ	MXPpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTByOUK5OUc,OjVyMEmyPVU9N2F-
SU-DHL-10	NFLoN5JCeG:ydH;zbZMhSXO\|YYm=	MX2xO\|IwOjVyIH7N	M4TrUldl	MX7EUXNQ	MYDpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	NXOzV4hERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNFkzQTVpPkK1NFA6Ojl3PD;hQi=>
Rosetta2 DE3	MUfGeY5kfGmxbjDhd5NigQ>?				M4fhb2tlKD1iMD6wNFYzKM7:TR?=	NHvISYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	NGT0VpJHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		NEjYT3A{OCCvaX7z		MWXLbUA:KDBwMEC2OkDPxE1?	NYTlN2lXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M130TGZ2dmO2aX;uJIF{e2G7				M1q1VGtlKD1iMD6wNFY4KM7:TR?=	M2DEU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	MVTGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		MmPjN\|AhdWmwcx?=		NYPaS5ZZU2liPTCwMlAxPzZizszN	M3S4[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M3rLWWZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		MV2zNEBucW6\|		M{fI[WtqKD1iMD6wNFg6KM7:TR?=	NXfvVFY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M2HBOGZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		Mnf4N\|AhdWmwcx?=		NEDZdXBMcSB;IECuNFExPyEQvF2=	M3vSOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	MX;GeY5kfGmxbjDhd5NigQ>?				Ml3LT4QhRSByLkCxNVch\|ryP	NYf3fZFqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
MV4-11	NWLHcHRUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		Mn;pO\|IhcA>?		M{fabGlEPTBiPTCwMlAyOiEQvF2=	NYnlOVZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
Rosetta2 DE3	NYTENFk5Tmy3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeR?=		NF7pU2E{OCCvaX7z		NWPJW\|ZIU2liPTCwMlAyOiEQvF2=	NIO2PFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
VCaP	MnjvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4\GXVEzKGh?		NGr3RVdKSzVyIE2gNE4xOTJizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
Rosetta2 DE3	MVjGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		NWX4dHU2OzBibXnudy=>		MoizT4khRSByLkCxNlUh\|ryP	M1HLc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	MoPJSpVv[3Srb36gZZN{[Xl?				Mn3TT4QhRSByLkCxNlgh\|ryP	MljQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MnPISox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDhd5NigQ>?		MmfGN\|AhdWmwcx?=		NIrveoZMcSB;IECuNFE{OiEQvF2=	NF33O5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	NGizVZZHfW6ldHnvckBie3OjeR?=				MoWyT4QhRSByLkCxN\|Yh\|ryP	NFvhe\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	MYXGeY5kfGmxbjDhd5NigQ>?				M122SmtlKD1iMD6wNVQ4KM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NFfOWJJHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		MWWzNEBucW6\|		NWTIZpVpU2liPTCwMlAyPDlizszN	MonLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
TY82	MlW1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NX62[3JnPzJiaB?=		M13TemlEPTBiPTCwMlAyQCEQvF2=	NYDmfXFxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OThpPkK4OVg3PzF6PD;hQi=>
MM1S	NFX0c3lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NHS3OGs4OiCq		MmHaTWM2OCB;IECuNFE6KM7:TR?=	Ml7YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OE[3NVgoRjJ6NUi2O\|E5RC:jPh?=
MM1S	NEPYbXhEgXSxdH;4bYNqfHliYYPzZZk>		MnrhO\|IhcA>?		NUT6VFBRUUN3MDC9JFAvODJizszN	NV;K[Y11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
HT-29	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		M{XXfFEzKGh?		MmjXTWM2OCB;IECuNFIh\|ryP	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV\|NUC0OUc,Ojh3M{WwOFU9N2F-
MV4-11	MmrsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVm3NkBp		NFLNRY1KSzVyIE2gNE4xOjNizszN	NVrhPIJ[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVk1OjhpPkK1OVU6PDJ6PD;hQi=>
MV4-11	M1\veWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NV\DTmN7PCCmYYnz		MmraTWM2OCB;IECuNFI1KM7:TR?=	NIHpVpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N\|Q5Pyd-Mki0OlM1QDd:L3G+
MV4-11	NFPnWZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVK0JIRigXN?		NVHsUWhSUUN3MDC9JFAvODJ2IN88US=>	NWPaT29oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	M2O2Z2Z2dmO2aX;uJIF{e2G7		NWH0OotbOzBibXnudy=>		Mn7STWM2OCB;IECuNFI5PyEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
NALM16	NFrWdWVEgXSxdH;4bYNqfHliYYPzZZk>		MW[1JIRigXN?		NF[3N2lGSzVyIE2gNE4xOyEQvF2=	NG[2PWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NFAzPCd-MkmxO\|AxOjR:L3G+
BL21(DE3)-R3-pRARE2	NET0WJpHfW6ldHnvckBie3OjeR?=		NEe3Wmg{OCCvaX7z		NXe2UFduUUN3MDC9JFAvODN\|IN88US=>	NFHnelE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5OVczOyd-MkixPVU4OjN:L3G+
BL21(DE3)	Mlj2SpVv[3Srb36gZZN{[Xl?				NX7I[WxXU2RiPTCwMlA{PCEQvF2=	M1T2UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{OxOFkxLz5{NkezNVQ6ODxxYU6=
Rosetta2 DE3	NG[5VHVHdHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7		NUjkNpA{OzBibXnudy=>		M4Hrd2lEPTBiPTCwMlA{PTdizszN	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	M2TaR2ZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gZZN{[Xl?		MnuzN\|AhdWmwcx?=		M{PhcmlEPTBiPTCwMlA1OjJizszN	M2q3cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
Rosetta2 DE3	MUjGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		NF62clg{OCCvaX7z		Ml;sTWM2OCB;IECuNFQ3PyEQvF2=	NXvReJZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
MOLM13	NX;QNVZIS3m2b4TvfIlkcXS7IHHzd4F6		NFvzclY1KGSjeYO=		M372VGlEPTBiPTCwMlA2PiEQvF2=	NHvqeZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N\|Q5Pyd-Mki0OlM1QDd:L3G+
MOLM13	NEXL[mFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1HTR\|Qh\GG7cx?=		MoPGTWM2OCB;IECuNFU3KM7:TR?=	M{DPbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
HL60	NFPKeVhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3O4XVczKGh?		M4DnWWlEPTBiPTCwMlA3KM7:TR?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
HL60	NXPteZVyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUKzJIRigXN?		NY\DSJQ4T0N3MDC9JFAvODZizszN	M1mzV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkW3NFk6Lz5{OU[1O\|A6QTxxYU6=
NALM6	MojJR5l1d3SxeHnjbZR6KGG\|c3H5		MY[1JIRigXN?		NVuwNYd4TUN3MDC9JFAvODZizszN	NEPmUVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW0PVg5QSd-Mki1OFk5QDl:L3G+
Raji	MnvVSpVv[3Srb36gZZN{[Xl?				NXnuOJNFUUN3MDC9JFAvODZizszN	NV\pN3BuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
Raji	NUizS5lKTnWwY4Tpc44h[XO\|YYm=		M1PKXVQhcA>?		MljVTWM2OCB;IECuNFY6KM7:TR?=	MkTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3OVgoRjJ2OUCwO\|U5RC:jPh?=
MM1S	MlnsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NWjsdJVKPzJiaB?=		NUThfplpUUN3MDC9JFAvODZ7MTFOwG0>	M37p[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUK1OFM2Lz5{OUWyOVQ{PTxxYU6=
BL21 (DE3)-codon plus-RIL	MYHGcJVwemW\|Y3XuZ4UheG:uYYLpfoF1cW:wIHHzd4F6		Mn:zZpkh\my3b4Lld4NmdmOnIHHubZNwfHKxcImgZZN{[Xl?		NEXGOHBKSzVyIE2gNE4xPyEQvF2=	NWnjTWJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OThpPkK4OVg3PzF6PD;hQi=>
22Rv1	Mke2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NFHqOI46PiCq		Ml\ETWM2OCB;IECuNFcyKM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
22Rv1	MnjFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4T5eFEzKGh?		NX\iWJVwUUN3MDC9JFAvODdzIN88US=>	M4HzWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
MV4-11	MmXwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				MnLsTWM2OCB;IECuNFczKM7:TR?=	NYLUT5JvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPVU4OjNpPkK4NVk2PzJ\|PD;hQi=>
BL21(DE3)-R3-pRARE2	Mo[0SpVv[3Srb36gZZN{[Xl?		M2H4eVMxKG2rboO=		MULJR\|UxKD1iMD6wO\|ch\|ryP	NUn6RotzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N\|E1QTBpPkK2O\|MyPDlyPD;hQi=>
BL21(DE3)-R3-pRARE2	MWnGeY5kfGmxbjDhd5NigQ>?		MY[zNEBucW6\|		M1r5TWlEPTBiPTCwMlA4PyEQvF2=	NFLBeGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5OVczOyd-MkixPVU4OjN:L3G+
BL21(DE3)-R3-pRARE2	NVSyN2k1TnWwY4Tpc44h[XO\|YYm=		M{Xn[VMxKG2rboO=		MX;JR\|UxKD1iMD6wO\|ch\|ryP	NV3vdYtlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|Y5OzRpPkK5O\|c3QDN2PD;hQi=>
MV4-11	NY[1T3c{S3m2b4TvfIlkcXS7IHHzd4F6		MXmyOEBp		MYrHTVUxKD1iMD6wPEDPxE1?	NVSy[5pxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPVE{PjNpPkK2NVkyOzZ\|PD;hQi=>
MV411	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NXLGeWV4PzJiaB?=		NX7jbpd1UUN3MDC9JFAvODhizszN	MnnqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUS1NVMoRjJ6M{G0OVE{RC:jPh?=
TY82	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NFy4SZE4OiCq		MlX6TWM2OCB;IECuNFgxQCEQvF2=	MkXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N\|UoRjJ7NUK1OFM2RC:jPh?=
HL60	MWDGeY5kfGmxbjDhd5NigQ>?		MWSyOEBp		NFLMe4pKSzVyIE2gNE4xQDZizszN	NX\FW4l1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
697	MX7DfZRwfG:6aXPpeJkh[XO\|YYm=		NGnocG42KGSjeYO=		NVPOeGZXTUN3MDC9JFAvODlizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
Loucy	Mlz4R5l1d3SxeHnjbZR6KGG\|c3H5		MX61JIRigXN?		NWT6U3czTUN3MDC9JFAvODlizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF5MECyOEc,OjlzN{CwNlQ9N2F-
BL21(DE3)	MYrGeY5kfGmxbjDhd5NigQ>?				MYLL[EA:KDBwMEmyJO69VQ>?	M{\IPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|cyLz5{OUW0NVM4OTxxYU6=
BL21(DE3)-R3-pRARE2	MWDGeY5kfGmxbjDhd5NigQ>?				NFLhd25M\CB;IECuNUDPxE1?	Ml3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3OUWwNFcoRjJ6NUm1NFA4RC:jPh?=
HT-29	M{DIS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NWX2ZnRFPzJiaB?=		NXe1Z21PUUN3MDC9JFAvOTB2IN88US=>	NVPKVIk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVk1OjhpPkK1OVU6PDJ6PD;hQi=>
MM1S	MlmwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXG3NkBp		M1;rPWlEPTBiPTCwMlExQSEQvF2=	M3PtOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW5OFI5Lz5{NUW1PVQzQDxxYU6=
LNCAP cells	MnrSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?				NVXIeVZkUUN3MDC9JFAvOTB7NjFOwG0>	M4nnU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
T cells	MXLGeY5kfGmxbjDhd5NigQ>?		NEL5V2gzPCCq		NYm2eYRyUUN3MDC9JFAvOTFizszN	NFuyN5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOFUyOyd-MkizNVQ2OTN:L3G+
HL60	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NEiybnE4OiCq		NUDZO4s3UUN3MDC9JFAvOTFizszN	NEPEWGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nki2PVE6PCd-Mk[4OlkyQTR:L3G+
BL21(DE3)	NFzzOoNHfW6ldHnvckBie3OjeR?=				NIT3XnJKSzVyIE2gNE4yOiEQvF2=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd\|MUS5NEc,OjZ5M{G0PVA9N2F-
BL21(DE3)	NFjUcFFHfW6ldHnvckBie3OjeR?=		NVHhfYNlOi53IHi=		NEnDZppKSzVyIE2gNE4yOiEQvF2=	NWDxWGt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
H1299	M1vQSWZ2dmO2aX;uJIF{e2G7		MXOyOEBp		NW[xfFlZTUN3MDC9JFAvOTV\|IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl2OUWyNUc,Ojh7NEm1NlE9N2F-
HD-MB03	NIXQUoFEgXSxdH;4bYNqfHliYYPzZZk>		M1nqcFUh\GG7cx?=		M{LmZWVEPTBiPTCwMlE3KM7:TR?=	NWTodWRYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
LNCAP	NGf5U2lCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MnfmPVYhcA>?		M{PYR2lEPTBiPTCwMlE3KM7:TR?=	NYG0[XpVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
Hs578T	NH:0PG9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NF;kbJEyOiCq		Mo\FTWM2OCB;IECuNVYh\|ryP	NYD5XpJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MV4-11	MmnjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M37wWVEzKGh?		NIXJSI5KSzVyIE2gNE4yPiEQvF2=	NFfwZWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG3NFAzPCd-MkmxO\|AxOjR:L3G+
LNCAP	NY[5fZVySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MlvQNVIhcA>?		NWDiflZbUUN3MDC9JFAvOTZizszN	NFTST2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
C4-2B	M2rFNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M3HtZVk3KGh?		Mlz3TWM2OCB;IECuNVkh\|ryP	NGH5W3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe1PFUyQCd-Mkm3OVg2OTh:L3G+
C4-2B	NVnPTnp1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NHvCbnAyOiCq		MXPJR\|UxKD1iMD6xPUDPxE1?	NV3RXXFIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
Vero E6	NVP0c4VDSW62aY\pdoFtKGGldHn2bZR6KGG\|c3H5		MV:0PEBp		MmjiTWM2OCB;IECuNVkzPzVizszN	Mm\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzJ\|NUO4OVkoRjN{M{WzPFU6RC:jPh?=
MCF7	NFz6OFVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NYPhOZl2OTJiaB?=		M3vheWlEPTBiPTCwMlIh\|ryP	NXLkd2lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MV4-11	NWHHU2NLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=				MW\JR\|UxKD1iMD6yOEDPxE1?	Ml;XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNEK3OVEoRjJ5MUSyO\|UyRC:jPh?=
MV4-11	Mkm5R5l1d3SxeHnjbZR6KGG\|c3H5		M1\M[lczKGh?		NGTmcHNKSzVyIE2gNE4zPDJizszN	NXrSUWNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVcxOTFpPkKzOVE4ODFzPD;hQi=>
MX1	NIn0OIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M3\XV\|czKGh?		NIXuXZlGSzVyIE2gNE4zPTRizszN	NV7mbZA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OFk2OjFpPkK4PVQ6PTJzPD;hQi=>
HT-29	M4LLOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NX6yNJlHPzJiaB?=		NVmyVHRNUUN3MDC9JFAvOjhizszN	NIrCVI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkezNVQ6OCd-Mk[3N\|E1QTB:L3G+
HFL1	NXXV[4NxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEPX[3oyOiCq		NXT4PHNMUUN3MDC9JFAvOjlizszN	NYXxcmRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
MDA-MB-231	NEOwXWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoXEN{Bl[Xm\|		MorqS2M2OCB;IECuN{DPxE1?	NUHEbZVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
MV4-11	Mn\nRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NUfYfpFyPDhiaB?=		MnuzSWM2OCB;IECuN\|MyOTNizszN	NUCzTplTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PVUxODdpPkK4OVk2ODB5PD;hQi=>
K562	NXnqVFR4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=				NH7aZ3FKSzVyIE2gNE43PCEQvF2=	MmnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzNEK3OVEoRjJ5MUSyO\|UyRC:jPh?=
HL60	MlHJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NUnXbIR5PDhiaB?=		MWjFR\|UxKD1iMD63OFE{OSEQvF2=	NF72RVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW5OVAxPyd-Mki1PVUxODd:L3G+
NCI-H1975	MmqzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MVGxNkBp		MUTJR\|UxKD1iMT6yN{DPxE1?	M1HzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
SAE	M173NWZ2dmO2aX;uJIF{e2G7		M3\uW\|QhcA>?		NVjU[JJpUUN3MDC9JFEvOzhizszN	NIS0T3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[0PVc1OSd-Mkm2OFk4PDF:L3G+
SAE	MlrvSpVv[3Srb36gZZN{[Xl?		Mnj0OEBp		M33MOWlEPTBiPTCxMlQ6KM7:TR?=	NGK2PHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[0PVc1OSd-Mkm2OFk4PDF:L3G+
SAE	M1HWPGZ2dmO2aX;uJIF{e2G7		MlmyOEBp		NXHq[WROUUN3MDC9JFEvPTFizszN	NVzPeYxvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2OFk4PDFpPkK5OlQ6PzRzPD;hQi=>
U2OS	NEf0cVVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MYGxNkBp		NXrHSYxMUUN3MDC9JFEvPjJizszN	M2PkTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{W4OVE5Lz5{OUe1PFUyQDxxYU6=
SAE	MV7GeY5kfGmxbjDhd5NigQ>?		NIniZ3U1KGh?		MYDJR\|UxKD1iMT62N{DPxE1?	NGj1Z\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[0PVc1OSd-Mkm2OFk4PDF:L3G+
A549	MmLGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4L2PFEzKGh?		MX3JR\|UxKD1iMT62O{DPxE1?	MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
MCF7	NXfodGcyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYKzJIRigXN?		NXn6eHVqT0N3MDC9JFEvPyEQvF2=	M2D0VFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUS5PFg6Lz5{OEW0PVg5QTxxYU6=
DU145	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NEjRSVA6PiCq		NUHacJltUUN3MDC9JFIvPTJizszN	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
DU145	Mn\BRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NFzncYEyOiCq		NGHN[49KSzVyIE2gNk42OiEQvF2=	NFzHeXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUW0NVM4OSd-Mkm1OFE{PzF:L3G+
T47D	NGLUXGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mkn6N{Bl[Xm\|		NHv3cGhISzVyIE2gNk45KM7:TR?=	NXnU[YZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OFk5QDlpPkK4OVQ6QDh7PD;hQi=>
PC3	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NXjjVHpwQTZiaB?=		NGLVPW9KSzVyIE2gN{4xOSEQvF2=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
PC3	NVTlNFlxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NGLNPW8yOiCq		M3\v[mlEPTBiPTCzMlAyKM7:TR?=	NVzONIN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
HeLa	M3HOSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NEG0[5QyOiCq		NYr0codtUUN3MDC9JFMvPzZizszN	NXS3NY9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O\|U5PTF6PD;hQi=>
K562	M2\RNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2jLdlMh\GG7cx?=		NELrOHFISzVyIE2gN{45KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV2OUi4PUc,Ojh3NEm4PFk9N2F-
A2780	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MoHSN{Bl[Xm\|		NUm3dXNiT0N3MDC9JFQh\|ryP	MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NEm4PFkoRjJ6NUS5PFg6RC:jPh?=
HL60	M1jTdWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEG5bpEzPCCq		NUf3PZlxUUN3MDC9JFUvOyEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ4Nkm5PUc,Ojd{Nk[5PVk9N2F-
MV4-11	NVfFcIhXS3m2b4TvfIlkcXS7IHHzd4F6		MYiyOEBp		MX\JR\|UxKD1iNj60JO69VQ>?	M4n2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5Mk[2PVk6Lz5{N{K2Olk6QTxxYU6=
K562	MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		Ml\uO\|IhcA>?		NWHkRoxSUUN3MDC9JFkvOTJizszN	MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUS1NVMoRjJ6M{G0OVE{RC:jPh?=
OVCAR5	NGXkZ5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MnnVN{Bl[Xm\|		NELV[GpISzVyIE2gNVIh\|ryP	MnuyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NEm4PFkoRjJ6NUS5PFg6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Water	Insoluble
	Ethanol	'91 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Target Protein Ligand Inhibitors with Unique Features

Pan BET Inhibitor

Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.
BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.
Classic BET Inhibitor

I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1